Chengzhi Zhou

机构：First Affiliated Hospital of Guangzhou Medical University, Kingmed Diagnostics, Guangdong Institute of Intelligent Manufacturing, State Key Laboratory of Respiratory Disease, Guangzhou Medical University · ORCID：0000-0002-1758-0035

发表论文 43 篇 · 总被引 548 次 · h-index 12

代表论文

• Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial (2023 · EClinicalMedicine · 被引 54)
• Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B) (2025 · Journal of Clinical Oncology · 被引 17)
• Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial (2023 · Journal of Thoracic Oncology · 被引 16)
• The influence of CLEC5A on early macrophage-mediated inflammation in COPD progression (2024 · Cellular and Molecular Life Sciences · 被引 13)
• Comorbidity of lung cancer and chronic obstructive pulmonary disease: correlation and optimization of treatment strategies (2025 · Translational Lung Cancer Research · 被引 6)
• Expert consensus on cancer treatment-related lung injury (2025 · Journal of Thoracic Disease · 被引 6)